Mucolytic to facilitate expectoration by reducing sputum viscosity.

• Adult: by inhalation of powder, over initiation dose (see product literature), then 400 mg, twice daily. The dose should be administered 5–15 minutes after a bronchodilator and before physiotherapy. The second daily dose should be taken 2–3 hours before bedtime.

Mucolytic 

Osmohale is used for an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness, a clinical feature of some respiratory conditions such as asthma.

Contraindications: Use with caution in renal impairment and to avoid in pregnancy. The Osmohale test should not be used in patients below 6 years of age due to their inability to provide reproducible spirometric measurements.

There is limited information on the use of Osmohale in patients 6-18 years of age therefore Osmohale is not recommended in this population.

Dose: See manufacturers’ instructions for more information. The test should be repeated until the patient has a positive response or 635 mg has been administered.